SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

8 Oct 2015 07:00

RNS Number : 5861B
Victrex PLC
08 October 2015
 



 

 

 

 

 

 

8 October 2015

 

Victrex plc - Full year pre-close trading update

 

"A good finish to 2015"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today announces its full year pre-close trading update for the financial year ended 30 September 2015, ahead of its preliminary results on 8 December 2015.

 

Victrex delivered a good finish to 2015, with overall performance in line with our expectations, including a robust fourth quarter (Q4). For the year as a whole, the value of our balanced portfolio helped to drive growth and fully overcome headwinds including weaker sales in Oil & Gas, the effects of US Spine market consolidation on our Invibio medical business and the significant impact from foreign currency this year.

 

On a reported basis, full year Group revenue of £263.5m was 4% ahead of the prior year (FY 2014: £252.6m), with Q4 Group revenue of £68.7m being flat on the prior year period. Foreign currency, at a profit level, was a headwind of approximately £8m for the full year, which we will fully overcome.

 

At a volume level, full year Group sales volume of 4,217 tonnes was 19% ahead of the prior year (FY 2014: 3,551 tonnes). Q4 Group sales volume of 1,119 tonnes was 6% ahead of the prior year period (Q4 2014: 1,056 tonnes). Sales volumes reflect our overall momentum in VPS remaining positive during the fourth quarter, with growth across Aerospace, Automotive, General Industrial and strong Consumer Electronics volumes offsetting Oil & Gas, as previously communicated.

 

Invibio performance was in line with our previous guidance, with full year revenue of £50.5m being 5% down compared to the prior year (FY 2014: £53.4m). This reflects the effects of consolidation in the US Spine market.

 

Outlook

Our overall growth momentum remains positive as we start our new financial year. Whilst we are mindful of the continuing weakness in Oil & Gas and the need to improve Invibio performance in 2016, our balanced portfolio keeps us well placed to continue driving growth and creating value, in line with our long term strategy.

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are delivering leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGQWUUPAGAM
Date   Source Headline
31st Mar 20102:22 pmRNSTotal Voting Rights
30th Mar 201010:28 amRNSHolding(s) in Company
29th Mar 20102:13 pmRNSHolding(s) in Company
29th Mar 20102:09 pmRNSDirector/PDMR Shareholding
29th Mar 20102:05 pmRNSHolding(s) in Company
22nd Mar 20103:14 pmRNSHolding(s) in Company
17th Mar 20103:36 pmRNSDirector/PDMR Shareholding
12th Mar 20102:43 pmRNSDirector/PDMR Shareholding
10th Mar 20104:11 pmRNSDirector/PDMR Shareholding
9th Mar 20102:55 pmRNSDirector/PDMR Shareholding
5th Mar 20102:08 pmRNSHolding(s) in Company
3rd Mar 20102:35 pmRNSDirector/PDMR Shareholding
26th Feb 201011:22 amRNSTotal Voting Rights
24th Feb 20101:39 pmRNSDirector/PDMR Shareholding
23rd Feb 201011:43 amRNSDirector/PDMR Shareholding
18th Feb 201012:28 pmRNSDirector/PDMR Shareholding
17th Feb 20103:15 pmRNSDirector/PDMR Shareholding
10th Feb 201012:18 pmRNSResult of AGM
9th Feb 20107:00 amRNSAGM and Interim Management Statement
8th Feb 201011:47 amRNSHolding(s) in Company
1st Feb 20101:50 pmRNSTotal Voting Rights
25th Jan 20103:36 pmRNSHolding(s) in Company
19th Jan 20104:09 pmRNSDirector/PDMR Shareholding
15th Jan 201011:21 amRNSDirector/PDMR Shareholding
7th Jan 201010:53 amRNSAnnual Information Update
6th Jan 201012:15 pmRNSTotal Voting Rights
18th Dec 20099:11 amRNSAnnual Financial Report
17th Dec 20093:38 pmRNSDirector/PDMR Shareholding
16th Dec 20094:56 pmRNSDirector/PDMR Shareholding
11th Dec 200911:22 amRNSHolding(s) in Company
8th Dec 20097:00 amRNSBoard and management changes
8th Dec 20097:00 amRNSFinal Results
4th Dec 20091:38 pmRNSHolding(s) in Company
1st Dec 20091:42 pmRNSBlocklisting Interim Review
30th Nov 20094:08 pmRNSTotal Voting Rights
17th Nov 20093:07 pmRNSDirector/PDMR Shareholding
30th Oct 20092:22 pmRNSTotal Voting Rights
20th Oct 200912:51 pmRNSDirector/PDMR Shareholding
8th Oct 20097:00 amRNSAnnual Trading Update
30th Sep 20092:53 pmRNSTotal Voting Rights
23rd Sep 20097:00 amRNSBoard Change
18th Sep 20091:58 pmRNSDirector/PDMR Shareholding
4th Sep 20092:15 pmRNSDirector/PDMR Shareholding
28th Aug 20092:13 pmRNSTotal Voting Rights
19th Aug 200910:49 amRNSDirector/PDMR Shareholding
6th Aug 20097:00 amRNSInterim Management Statement
31st Jul 200912:06 pmRNSTotal Voting Rights
24th Jul 20091:13 pmRNSDirector/PDMR Shareholding
17th Jul 20092:24 pmRNSDirector/PDMR Shareholding
30th Jun 20093:38 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.